Watch: Bristol-Myers Squibb has taken a step toward closing its deal for Celgene with the $13 billion sale of the latter’s psoriasis drug to Amgen. The rich price lends credence to Bristol-Myers’ claim that Celgene was undervalued, says richardbeales1.
Bristol-Myers Squibb has taken a step toward closing its deal for Celgene with the $13 bln sale of the latter’s psoriasis drug to Amgen. Richard Beales says the rich price lends credence to Bristol-Myers’ claim that Celgene was undervalued, and deserving of its $74 bln offer.
https://reut.rs/2ZoUtpn
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Celgene to sell psoriasis drug Otezla for $13.4 billion to AmgenCelgene Corp will sell its psoriasis drug Otezla for $13.4 billion in cash to Am...
Read more »
Amgen to buy Celgene psoriasis drug Otezla for $13.4 billionAmgen Inc will buy Celgene Corp's psoriasis drug Otezla for $13.4 billion i...
Read more »
Stocks making the biggest moves midday: Dish Network, Bristol-Myers Squibb, Beyond Meat & moreThese are the stocks posting the largest moves midday.
Read more »
Bristol-Myers passes $74 bln deal’s first big examThe drugmaker is stretching to buy rival Celgene. To smooth U.S. antitrust review, it put its target’s blockbuster psoriasis treatment on the market. Amgen has won that prize, for an unexpectedly rich $13 bln. That’s a boost for Bristol-Myers’ deal rationale – and its timing.
Read more »
Rosalía Is Set to Deliver a Knockout VMAs PerformanceThe singer-songwriter fuses classic flamenco sounds with modern beats.
Read more »